The State of Inquiry
Latest Episode
Host Dr. Kevin Jones examines how AI is rapidly reshaping our world in what he calls the Age of Accelerated Transformation.
State of Inquiry is a video and audio podcast from Indiana Public Media that brings Indiana University research to life. Each mini-season explores a timely theme—like artificial intelligence, public health, or global economics—through in-depth conversations with IU experts. Designed for curious listeners, the show highlights how IU research shapes Indiana, the nation, and the world.
Rural Indiana
Hope in Progress
AI & You
All Episodes
-
Host Dr. Kevin Jones examines how AI is rapidly reshaping our world in what he calls the Age of Accelerated Transformation.
-
Explore how land, food systems, and rural values shape decision-making across Indiana’s agricultural communities.
-
A conversation about how rural residents engage with local news, why trust is shifting, and what it means for civic life and the future of journalism.
-
An in-depth look at rural Indiana’s greatest public health challenges and how Indiana communities are building solutions that fit their needs.
-
A conversation about the pressures facing rural communities and the innovative ways residents and local leaders are building stronger, more sustainable futures across Indiana.
-
What if you could make cancer cells more vulnerable by targeting DNA repair?
-
How does our metabolism affect cancer growth? How do cancer cells “eat” and how do they communicate and compete with other cells? Learn about the latest research into how cancer cells adapt at a metabolic level, using nutrients to proliferate, evade cell death, and persist after therapy.
-
What if the most important drivers of cancer aren’t mutations in DNA, but the chemical switches that control how cells read that DNA?
-
How does our understanding of environmental exposures and our own hormones shape how we can predict, detect, and treat lung cancer?
-
Triple-negative breast cancer is aggressive and hard to treat. How are new therapies and early phase clinical trials changing what’s possible for patients?
